Quotient Sciences

Nottingham, United Kingdom
Small Molecule (Oral Solid Dose) HPAPI / High-Potency API Modified Release Pediatric Formulation Oral Peptide Solubility Enhancement (SDD, HME, Nanoparticulate) Clinical Pharmacology (Phase I CRO)
Program data pending ClinicalTrials.gov matching
60.0
Signal Score
○ FDA Inspections ○ Clinical Trials ○ SEC Filings ✓ Press (10) ○ EMA GMP ○ MHRA GMP

Quick Facts: Quotient Sciences

Signal Score
60.0/100
Quality Compliance
Assessment pending
Headquarters
Nottingham, United Kingdom
Modalities
Small Molecule (Oral Solid Dose), HPAPI / High-Potency API, Modified Release, Pediatric Formulation, Oral Peptide, Solubility Enhancement (SDD, HME, Nanoparticulate), Clinical Pharmacology (Phase I CRO)
Active Programs
No ClinicalTrials.gov matches confirmed
Data Sources
FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
Scored By
CDMO Signal — independent CDMO intelligence platform

About Quotient Sciences

Auto-created by AI matchmaker. Data verification pending.

Signal Score & Pillar Breakdown

Quality Compliance
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs no verified data
Sponsorsno verified data
ModalitiesSmall Molecule (Oral Solid Dose), HPAPI / High-Potency API, Modified Release, Pediatric Formulation, Oral Peptide, Solubility Enhancement (SDD, HME, Nanoparticulate), Clinical Pharmacology (Phase I CRO)
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability 60.0
Private company
Financial assessment: 60.0/100
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity 60.0
Broad modality coverage (7 modalities)
Source: SEC EDGAR, press monitoring, company profiles
Profile-based capacity assessment
Recent Press10 articles
Broad modality coverage (7 modalities)

Recent News 10 articles

news Wed, 15 No
Acquisitive Quotient buys CDMO Pharmaterials, reveals new identity - Fierce Biotech
news Tue, 30 De
Pharma in 2025–2026: AI, China and the new era of drug development - Manufacturing Chemist
news Tue, 17 Oc
Thierry Van Nieuwenhove Appointed as CEO of Quotient Sciences - CHEManager
news Tue, 14 Oc
Quotient Sciences and Biorasi partner to accelerate early phase clinical trials to patient proof-of-concept - PR Newswire
news Tue, 09 Fe
Quotient Sciences Acquires Arcinova, the UK-Based Contract Development and Manufacturing Organization - Business Wire
news Tue, 01 Oc
CEO Spotlight: Thierry Van Nieuwenhove - Contract Pharma
news Thu, 26 Ma
CDMO Roundtable: Managing Orphan Drug Projects - DCAT Value Chain Insights
news Thu, 02 Se
Quotient Sciences casts $8.7M spell over its new Alnwick facility, adding drug substance capacity and 80 jobs - Fierce Pharma
news Mon, 02 Ma
CDMO Quotient extends Ipsen supply pact for rare disease drug Sohonos - Fierce Pharma
news Fri, 11 Fe
Quotient's streamlined drug development process saves months - Pharmaceutical Technology

Frequently Asked Questions About Quotient Sciences

What is Quotient Sciences's CDMO Signal Score?
Quotient Sciences has a Signal Score of 60/100, based on quality, operations, financial stability, and capacity data.
Evaluating Quotient Sciences for a manufacturing program?
Use the free AI matchmaker to compare Quotient Sciences against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
HPAPI / High-Potency API CDMOs →

Similar CDMOs

Altasciences
Laval, Canada
Small Molecule (Oral Solid Dose), Capsules (liquid-filled, gelatin, hypromellose), HPAPI / High-Potency API, Formulation Development, Analytical & Stability Testing, Clinical Trial Material Manufacturing, Phase I–Commercial Scale Manufacturing
Bend Bioscience
Bend, OR
Spray Dried Dispersion (SDD), Amorphous Solid Dispersion (ASD), Particle Engineering, Oral Solid Dose, Multiparticulates, Modified Release, Small Molecule API
Serán Bioscience
Bend, OR
Small Molecule (Oral Solid Dose), Spray Dried Dispersion (SDD), Hot Melt Extrusion (HME), Nano-milling / Nanoparticulate, Fluid Bed Processing, Particle Engineering, Pulmonary / Inhaled Particulates, Nasal Drug Delivery, Finished Dose (tablets, capsules, OPCs, powder-in-bottle)
Bora Pharmaceuticals
Taipei, Taiwan
Small Molecule (Oral Solid Dose), Biologics (Drug Substance & Drug Product), Monoclonal Antibody, Sterile Injectables / Aseptic Fill-Finish, Semi-Solids (creams, ointments, gels), Liquids (solutions, suspensions, ophthalmics, nasal sprays), Lyophilization
Glatt Pharmaceutical Services
Binzen, Germany
Multiparticulate Systems, Pellets, Micropellets, Granules, Fluid Bed Coating, Wurster Coating, Spray Coating, Modified Release, Oral Solid Dose